 |
인쇄하기
취소
|
Boryung grants Stendhal exclusive rights to Kanarb, novel antihypertensive agent
Boryung Pharmaceutical has granted Latin American specialty company Stendhal exclusive commercialization rights for Mexico, Venezuela, Colombia, Perú, Ecuador and most of Central American countries, to its novel antihypertensive drug Kanarb (fimasartan).
Under the terms of the agreement, Stendhal will pay both upfront fees ($3 million) and running royalty on sales for the life of the contrac...
Under the terms of the agreement, Stendhal will pay both upfront fees ($3 million) and running royalty on sales for the life of the contrac...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.